3SBio Forms China Partnership with Verseau for Macrophage Checkpoint Modulators
publication date: Feb 11, 2019
3SBio of Shenyang invested $15 million into Boston's Verseau Therapeutics and will partner with Verseau to develop its macrophage checkpoint modulators (MCMs) in Greater China for various cancers. 3SBio will be responsible for antibody development, GMP manufacturing and commercialization in China, Taiwan, Hong Kong and Macau, while Verseau will supply the targets. 3SBio and Verseau will each be eligible to receive milestone payments and sales-based royalties, though details of the agreement were not disclosed. More details....
Stock Symbol: (HK:1530)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.